<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605538</url>
  </required_header>
  <id_info>
    <org_study_id>2012/251-31/2</org_study_id>
    <nct_id>NCT02605538</nct_id>
  </id_info>
  <brief_title>Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively</brief_title>
  <official_title>Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients
      according to European consensus. The aim of the study is to vaccinate as many patients as
      possible and to follow up whether immunization has been complete.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initially, healthy volunteers will be vaccinated to be compared with patients' antibody
      response to hepatitis A and B vaccine.

      The connected part of this study is to vaccinate children suffering from latent tuberculosis
      against hepatitis B and to measure whether the immunization is related to specific interferon
      gamma response against Mycobacterium tuberculosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive antibody response to vaccination with Twinrix(TM) in CF patients compared to healthy volunteers</measure>
    <time_frame>6 months for vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Hepatitis A</condition>
  <condition>Hepatitis B</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Cystic Fibrosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with vaccine against hepatitis A and B</intervention_name>
    <description>Vaccination against hepatitis A and B</description>
    <arm_group_label>Cystic Fibrosis</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <other_name>Twinrix (TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CF patients not previously immunized against hepatitis A or B

          -  Healthy volunteers not previously immunized against hepatitis A or B

          -  Age over 1 year

        Exclusion Criteria:

          -  Previously transplanted patients

          -  Previous vaccination with hepatitis vaccine

          -  Known allergy against components in Twinrix (TM)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferenc Karpati, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stockholm CF Center, Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ferenc Karpati, MD, PhD</last_name>
    <phone>+46-8-58580000</phone>
    <phone_ext>81656</phone_ext>
    <email>ferenc.karpati@karolinska.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Hollander, RN</last_name>
    <phone>+46-8-58580000</phone>
    <phone_ext>81652</phone_ext>
    <email>anna.hollander@karolinska.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stockholm CF Center, KArolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferenc Karpati, MD, PhD</last_name>
      <email>ferenc.karpati@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Anna Hollander, RN</last_name>
      <email>anna.hollander@karolinska.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Ferenc Karpati</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

